Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from A ncBAF to cBAF Switch Regulates Human Hematopoietic Progenitor Myeloid Differentiation. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/cr.2011.32
10.1038/cr.2011.32 · External reference
10.1016/j.cell.2018.09.032
10.1016/j.cell.2018.09.032 · External reference
10.1101/sqb.2016.81.031021
10.1101/sqb.2016.81.031021 · External reference
10.1016/j.neuron.2007.06.019
10.1016/j.neuron.2007.06.019 · External reference
10.1073/pnas.0812889106
10.1073/pnas.0812889106 · External reference
The BAF chromatin remodelling complex is an epigenetic regulator of lineage specification in the early mouse embryo. Development (Cambridge
2016 · External reference
10.1186/s12943-023-01736-8
10.1186/s12943-023-01736-8 · External reference
BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state
10.1038/s41467-023-44081-6 · 2023 · External reference
10.1038/s41588-023-01471-2
10.1038/s41588-023-01471-2 · External reference
10.1158/2159-8290.cd-18-1474
10.1158/2159-8290.cd-18-1474 · External reference
10.1038/s41556-018-0221-1
10.1038/s41556-018-0221-1 · External reference
10.1073/pnas.2110812119
10.1073/pnas.2110812119 · External reference
10.1016/j.immuni.2020.06.011
10.1016/j.immuni.2020.06.011 · External reference
10.1158/1538-7445.am2022-nd09
10.1158/1538-7445.am2022-nd09 · External reference
10.1158/1078-0432.ccr-24-2583
10.1158/1078-0432.ccr-24-2583 · External reference
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
10.1158/1078-0432.ccr-24-2583 · 2025 · External reference
10.1038/s41586-019-1646-9
10.1038/s41586-019-1646-9 · External reference
BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements
10.1016/j.celrep.2016.03.054 · 2016 · External reference
Amx-883, a potent and selective degrader of BRD9 drives differentiation in acute myeloid leukaemia and shows synergistic efficacy in combination with venetoclax In Vivo and prevents the emergence of resistance to venetoclax in vitro
10.1182/blood-2025-1489 · 2025 · External reference
10.1074/jbc.ra117.001065
10.1074/jbc.ra117.001065 · External reference
10.1073/pnas.1711155115
10.1073/pnas.1711155115 · External reference
Brd4 binds to active enhancers to control cell identity gene induction in adipogenesis and myogenesis
10.1038/s41467-017-02403-5 · 2017 · External reference
10.1021/acs.jmedchem.5b00256/suppl_file/jm5b00256_si_001.pdf
10.1021/acs.jmedchem.5b00256/suppl_file/jm5b00256_si_001.pdf · External reference
BRD9-containing non-canonical BAF complex maintains somatic cell transcriptome and acts as a barrier to human reprogramming
10.1016/j.stemcr.2022.10.005 · 2022 · External reference
BRD9-mediated chromatin remodeling suppresses osteoclastogenesis through negative feedback mechanism
10.1038/s41467-023-37116-5 · 2023 · External reference
10.1038/s41590-022-01189-z
10.1038/s41590-022-01189-z · External reference
10.1182/blood-2015-01-621631
10.1182/blood-2015-01-621631 · External reference
10.3389/fmolb.2022.723846
10.3389/fmolb.2022.723846 · External reference
10.1182/blood-2003-12-4415
10.1182/blood-2003-12-4415 · External reference
10.1126/science.1092385
10.1126/science.1092385 · External reference
10.1038/nri.2017.105
10.1038/nri.2017.105 · External reference
10.1126/sciimmunol.aay6017
10.1126/sciimmunol.aay6017 · External reference
10.1093/database/baz046
10.1093/database/baz046 · External reference
SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities
10.3389/fimmu.2019.01369 · 2019 · External reference
10.1038/ncomms12150
10.1038/ncomms12150 · External reference
Myeloid-derived suppressor cells in cancer and cancer therapy
10.1038/s41571-023-00846-y · 2024 · External reference
10.1158/0008-5472.can-15-2528
10.1158/0008-5472.can-15-2528 · External reference
10.1016/j.celrep.2024.114558
10.1016/j.celrep.2024.114558 · External reference
10.1038/s41375-019-0438-4
10.1038/s41375-019-0438-4 · External reference
10.1038/s41591-020-0856-x
10.1038/s41591-020-0856-x · External reference
10.1038/s41591-020-0860-1
10.1038/s41591-020-0860-1 · External reference
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
10.1186/s40425-019-0706-x · 2019 · External reference
10.1016/j.ctrv.2017.08.004
10.1016/j.ctrv.2017.08.004 · External reference
10.1189/jlb.0113040
10.1189/jlb.0113040 · External reference
10.1172/jci.insight.94296
10.1172/jci.insight.94296 · External reference
10.7150/thno.17138
10.7150/thno.17138 · External reference
S100A8/A9 activate key genes and pathways in colon tumor progression
10.1158/1541-7786.mcr-10-0394 · 2011 · External reference
